© 2021 MJH Life Sciences™ and Contemporary Pediatrics. All rights reserved.
Dermatology
FDA approval given to dalbavancin for acute skin infections
July 28, 2021
Dalbavancin has received US Food and Drug Administration (FDA) approval to treat acute bacterial skin and skin structure infections in pediatric patients.
Looking at systemic treatment for atopic dermatitis
July 21, 2021
New and forthcoming options bring opportunity for optimizing patient care.
A case of lime disease
July 09, 2021
A 17-year-old boy presents with linear brown spots on his abdomen and chest that developed when he was on a beach vacation with his family the week prior. What's the diagnosis?
Using dupilumab for pediatric alopecia areata
July 01, 2021
Hair regrowth was observed after starting dupilumab treatment in some pediatric patients with a history of severe and refractory alopecia areata and concomitant atopic dermatitis.
When hemangioma indicates PHACE risk
June 21, 2021
Not all infants with infantile hemangiomas are at risk of PHACE (posterior fossa malformations, hemangioma, arterial anomalies, cardiac defects, eye anomalies) syndrome, but some characteristics may indicate an increased risk.
Caregivers worry about impact of severe acne on teens
June 16, 2021
More than 90% of respondents to a recent survey expressed concern about acne’s effect on their adolescent’s mental health and social life.
Congenital malalignment syndrome
June 11, 2021
A 13-year-old girl presents with great toenails have become yellow, thickened, ridged, and crusted proximally on the left over the last 8 months.
Certain probiotics may reduce the risk of atopic dermatitis
June 02, 2021
Can probiotics help with atopic dermatitis risk? A meta-analysis offers some answers.
FDA approves Cosentyx for kids aged 6 and older
June 02, 2021
The US Food and Drug Administration (FDA) approved Cosentyx® (secukinumab) to treat moderate-to-severe plaque psoriasis in children aged 6 years and older. It’s the first pediatric approval for the drug.